Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merus N.V. CS (NQ: MRUS ) 52.62 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 3 Open 52.62 Bid (Size) 21.05 (2) Ask (Size) 55.00 (1) Prev. Close 52.62 Today's Range 52.62 - 52.62 52wk Range 19.80 - 61.61 Shares Outstanding 46,530,884 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC September 30, 2024 From Merus N.V. Via GlobeNewswire Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024 September 17, 2024 Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation From Merus N.V. Via GlobeNewswire Performance YTD +83.86% +83.86% 1 Month +5.92% +5.92% 3 Month -5.77% -5.77% 6 Month +22.12% +22.12% 1 Year +149.98% +149.98% More News Read More Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference August 06, 2024 From Merus N.V. Via GlobeNewswire MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024 August 01, 2024 Via InvestorPlace Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update August 01, 2024 From Merus N.V. Via GlobeNewswire Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC July 24, 2024 From Merus N.V. Via GlobeNewswire Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC July 08, 2024 From Merus N.V. Via GlobeNewswire Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer July 01, 2024 From Merus N.V. Via GlobeNewswire Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting June 03, 2024 From Merus N.V. Via GlobeNewswire Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting June 02, 2024 From Merus N.V. Via GlobeNewswire Merus Announces Pricing of Upsized Public Offering of Common Shares May 29, 2024 From Merus N.V. Via GlobeNewswire Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference May 29, 2024 From Merus N.V. Via GlobeNewswire Merus N.V. Announces Proposed Public Offering of Common Shares May 28, 2024 From Merus N.V. Via GlobeNewswire Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 28, 2024 Via Benzinga Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC May 28, 2024 From Merus N.V. Via GlobeNewswire Crude Oil Rises 1%; Verastem Shares Slide May 24, 2024 Via Benzinga Exposures Fossil Fuels Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session May 24, 2024 Via Benzinga Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday? May 24, 2024 Via Benzinga Nasdaq Gains 1%; Intuit Shares Plunge May 24, 2024 Via Benzinga Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High May 24, 2024 Via Investor's Business Daily Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday May 24, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 24, 2024 Via InvestorPlace Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting May 23, 2024 From Merus N.V. Via GlobeNewswire Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting May 23, 2024 From Merus N.V. Via GlobeNewswire Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA May 13, 2024 From Merus N.V. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
